Show simple item record

Gastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogs

dc.contributor.authorMummaneni, Vanajaen_US
dc.contributor.authorDressman, Jennifer B.en_US
dc.contributor.authorAmidon, Gordon L.en_US
dc.date.accessioned2006-09-08T19:15:53Z
dc.date.available2006-09-08T19:15:53Z
dc.date.issued1995-05en_US
dc.identifier.citationMummaneni, Vanaja; Amidon, Gordon L.; Dressman, Jennifer B.; (1995). "Gastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogs." Pharmaceutical Research 12(5): 780-786. <http://hdl.handle.net/2027.42/41444>en_US
dc.identifier.issn1573-904Xen_US
dc.identifier.issn0724-8741en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41444
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=7479568&dopt=citationen_US
dc.description.abstractThe plasma concentration-time profiles of cimetidine often exhibit two peaks following oral administration of a single dose in the fasted state, while the concurrent administration of some antacids results in a lower extent as well as rate of absorption. In the present work, absorption of cimetidine after a single dose in the fasted state was studied as a function of gastric pH in male beagle dogs to determine whether gastric pH plays a role in the double peak phenomenon and/or can account for the decrease in bioavailability when antacids are coadministered. The extent of absorption of cimetidine was not influenced significantly by gastric pH, indicating that elevation of gastric pH is not the cause of decreases in the bioavailability of cimietidine when it is administered with antacids. Distinct double peaks or plateaux were noted in 8 of 10 plasma profiles when the gastric pH was 3 or below. Irregular absorption behavior was observed in 2 of 6 profiles in the pH range of 3 to 5, while single peaks were observed in all 10 profiles when the gastric pH was maintained at pH ≥ 5. It was concluded that gastric pH is a major factor in the generation of cimetidine double peaks. Changes in gastric pH also resulted in changes in the apparent kinetics of absorption. Below pH 5, absorption mostly followed zero-order kinetics (9 of 16 profiles) or a more complex kinetic process involving at least two components to the absorption phase (5 of 16 profiles). At gastric pH ≥ 5, however, absorption followed first order kinetics in 7 of 10 profiles. These differences in kinetics of absorption are postulated to arise from variations in gastric emptying as a function of pH and/or carryover effects of gastric pH into the upper intestine.en_US
dc.format.extent1245611 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherCimetidineen_US
dc.subject.otherBioavailabilityen_US
dc.subject.otherPharmacyen_US
dc.subject.otherGastric PHen_US
dc.subject.otherDouble Peaksen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherMedical Lawen_US
dc.subject.otherAbsorption Rate Constanten_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherIntestinal PHen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherGastric Emptyingen_US
dc.titleGastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065; Institut für Pharmazeutische Technologic, J. W. Goethe-Universität, Marie Curie Str. 9, D-60439, Frankfurt am Main, Germanyen_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065; Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey, 08543-4000en_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, Ann Arbor, Michigan, 48109-1065en_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid7479568en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41444/1/11095_2004_Article_306899.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1016284214708en_US
dc.identifier.sourcePharmaceutical Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.